OvaScience (OVAS) Shares Up 5.6%
Shares of OvaScience Inc. (NASDAQ:OVAS) traded up 5.6% during trading on Wednesday . The company traded as high as $1.56 and last traded at $1.50. 3,670,100 shares changed hands during mid-day trading, an increase of 541% from the average session volume of 572,867 shares. The stock had previously closed at $1.42.
A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Wednesday, October 4th. Oppenheimer restated a “hold” rating on shares of OvaScience in a report on Thursday, August 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of OvaScience in a research note on Monday, November 6th.
Institutional investors have recently modified their holdings of the company. Jennison Associates LLC grew its holdings in shares of OvaScience by 0.4% in the 2nd quarter. Jennison Associates LLC now owns 2,191,258 shares of the biotechnology company’s stock worth $3,418,000 after purchasing an additional 7,731 shares during the last quarter. GMT Capital Corp acquired a new stake in shares of OvaScience in the 3rd quarter valued at approximately $1,138,000. Sabby Management LLC increased its stake in OvaScience by 20.2% during the 2nd quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock worth $795,000 after purchasing an additional 85,525 shares in the last quarter. Legal & General Group Plc increased its stake in OvaScience by 4,654.1% during the 2nd quarter. Legal & General Group Plc now owns 458,822 shares of the biotechnology company’s stock worth $713,000 after purchasing an additional 449,171 shares in the last quarter. Finally, Broadfin Capital LLC acquired a new stake in OvaScience during the 2nd quarter valued at $429,000. Institutional investors and hedge funds own 55.30% of the company’s stock.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.